Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Evaluate the biopharma company tavneos on oral complement pathway inhibitor?Ozempic list price 2023 united states 1 mg pen monthly supply?Keytruda patent expiry india?Benefits of branded ibuprofen over generic?Isometheptene dichloralphenazone acetaminophen images?
See the DrugPatentWatch profile for dapagliflozin
Dapagliflozin 10 mg is an SGLT2 inhibitor used to treat certain people with: - Type 2 diabetes (to improve blood sugar control) - Chronic kidney disease (to help slow worsening of kidney function) - Heart failure (to reduce the risk of cardiovascular death and hospitalization, depending on the type of heart failure and patient profile)
Dapagliflozin lowers blood glucose by helping the kidneys remove glucose through the urine. This kidney effect is also part of why it can benefit people with chronic kidney disease and heart failure, even when blood sugar is not the main issue.
The “10 mg” strength refers to a common fixed daily dose used for its approved indications. Other dosing schedules may exist depending on the specific condition and the prescribing label, but 10 mg is a standard regimen for many patients.
It is generally prescribed for adults who have: - Type 2 diabetes, particularly when clinicians want both glucose lowering and added cardiovascular/kidney protection - Chronic kidney disease - Heart failure The exact eligibility depends on kidney function, heart failure type, and other medical factors.
No provided sources were available to cite for this answer.
Other Questions About Dapagliflozin :